ASCO 2013 - Chicago - Chronic Myeloid Leukemia
See Abstracts about Leukemia
ARIAD Announces Long-Term Durability-of-Response Data on Ponatinib from Ongoing Phase 1 Study
Jun 2nd 2013, DailyFinance
2013 ASCO EDUCATIONAL BOOK
Overcoming Resistance in Chronic Myelogenous Leukemia by Dr. Michael J. Mauro
ABSTRACTS ABOUT CML
Impact of baseline mutations on response to ponatinib and end of
treatment mutation analysis in patients with chronic myeloid leukemia.
Management of chronic myeloid leukemia in chronic phase (CML-CP) by American
Hematology-Oncology Physicians (AHOP's): Diagnostic and treatment preferences
after first-line imatinib (2010-2012).
Effect of dose-optimized imatinib (IM) 800 mg on deep molecular
responses (CMR 4.5) and prediction of survival: Results from the randomized
Nilotinib versus imatinib in patients (pts) with newly diagnosed
chronic myeloid leukemia in chronic phase (CML-CP): ENESTnd 4-year (y) update.
Switching patients (pts) with chronic myeloid leukemia in chronic
phase (CML-CP) with residual disease on long-term imatinib (IM) to nilotinib
(NIL): ENESTcmr 24-mo follow-up.
Impact of early molecular response to nilotinib (NIL) or imatinib
(IM) on the long-term outcomes of newly diagnosed patients (pts) with chronic
myeloid leukemia in chronic phase (CML-CP): Landmark analysis of 4-year (y) data
Outcome of pregnancy in women on imatinib for CML.
Treatment response monitoring in chronic phase CML (CP-CML)
patients receiving tyrosine kinase inhibitor (TKI) therapy in US Oncology
Post hoc analysis of sustained efficacy/tolerability of ≥12
cycles of omacetaxine mepesuccinate in chronic myeloid leukemia (CML).
Omacetaxine mepesuccinate in chronic phase chronic myeloid
leukemia (CML-CP): A post hoc analysis of myelosuppression.
Plasma trough imatinib levels and molecular response in patients
of chronic myeloid leukemia (CML): A single institution study from India.
Phase I study of NRC-an-019, a tyrosine kinase inhibitor, in
imatinib-resistant chronic myeloid leukemia (CML) in an Indian tertiary care
Predictive factors associated with achievement of major
cytogenetic response (MCyR) to omacetaxine mepesuccinate among patients with
chronic phase chronic myeloid leukemia (CML-CP).
Incidence and outcomes of chronic myeloid leukemia (CML) patients
(pts) treated with second-generation tyrosine kinase inhibitors (TKI) who
develop other chromosomal abnormalities (OCA).
Economic benefits of adequate molecular monitoring in patients
with chronic myelogenous leukemia (CML).
Types, frequency, and adherence of molecular tests in chronic
myelogenous leukemia at chronic phase (CML-CP) in the U.S. community setting.
EPIC: A phase III randomized, open-label study of ponatinib
versus imatinib in adult patients with newly diagnosed chronic myeloid leukemia
in chronic phase.
Imatinib dose hike in suboptimal response and failure in CML CP:
Results from a developing nation.
Analysis of survival in patients with chronic myelogenous
leukemia in pre- and post-imatinib era involving comparison of large academic
medical center versus national data: The Beaumont experience.
The experience in the management of 15 patients with chronic myeloid leukemia (CML)
in a community clinic in Puerto Rico.